Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November 2024

Commission File No. 001-35193

Grifols, S.A.

(Translation of registrant’s name into English)

Avinguda de la Generalitat, 152-158

Parc de Negocis Can Sant Joan

Sant Cugat del Valles 08174

Barcelona, Spain

(Address of registrant’s principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Grifols, S.A.

TABLE OF CONTENTS

Item		Sequential Page Number

1.	Inside Information Note, dated November 19, 2024	3

	Grifols, S.A.

	Avinguda de la Generalitat 152-158
	08174 Sant Cugat del Vallès
	Barcelona - ESPAÑA

	Tel. [34] 935 710 500
	Fax [34] 935 710 267

	www.grifols.com

Pursuant to the provisions of article 226 of the Consolidated Text of the Securities Market Act, approved by the Legislative Royal Decree 4/2015, of 23 October, Grifols, S.A. ("Grifols") hereby informs about the following

INSIDE INFORMATION

In relation to the inside information note sent today to the CNMV by Brookfield Capital Partners (UK) Limited, Grifols announces that its Board of Directors will hold an extraordinary meeting this afternoon to analyse the information received. Subsequently, it will issue an opinion regarding Brookfield's communication. The directors who are in conflict of interest will not participate in the issuance of such opinion.

Grifols also announces that the Transaction Committee of the Board of Directors has duly considered Brookfield’s non-binding indicative valuation of €6.45Bn for the entire outstanding share capital of the Company (the aggregate of Class A and B shares), implying an indicative price of €10.50 per share for Class A shares, and has concluded that a potential offer at this valuation level significantly undervalues the Company’s fundamental prospects and its long-term potential. Accordingly, the Transaction Committee would not be in a position to recommend to the Board of Directors to support an offer at this valuation for the Company nor to recommend to the shareholders of the Company the acceptance of a potential offer at the indicated price. The Transaction Committee communicated this fact to Brookfield and has requested the call for the extraordinary meeting referred to above.

In Barcelona, on 19 November 2024.

Thomas Glanzmann

Chairman of the Board of Directors

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.